Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-984923 in Healthy Older Adults and Alzheimer's Disease
NCT05804383Phase 1Completed
- Sponsor
- Allyx Therapeutics
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-9894923 in Alzheimer's disease (AD) (11 arms), sponsored by Allyx Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Clinically Significant Laboratory Abnormalities and 1 more. Started Mar 2023; status: completed.
02
Drugs
BMS-9894923
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05804383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804383.